<DOC>
	<DOCNO>NCT02577718</DOCNO>
	<brief_summary>The objective Phase I/II pilot study evaluate safety effectiveness non- antibiotic chelator base lock solution contain nitroglycerin combination sodium citrate ethanol ( NiCE lock solution ) prevention central line associate bloodstream infection ( CLABSI ) . - The primary objective study evaluate safety estimate rate adverse event associate NiCE lock solution . - The second primary objective estimate rate CLABSI patient receive NiCE lock solution .</brief_summary>
	<brief_title>Safety Effectiveness Novel Nitroglycerin Based Catheter Lock Solution</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Catheter-Related Infections</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Inpatients long term central venous catheter ( CVC ) â€”and CVC place least 14 day expect remain place least 30 day enrollment The CVC consist 5.0 French size , duallumen , peripherally inserted central catheter Patients willing capable provide Informed Consent Patients willing capable follow instruction require complete study Females ( child bear potential ) male ( child bear potential ) must abstinent agree use birth control study . Patients antimicrobial CVC . Patients short term CVC place ICU ( mainly rigid wall CVCs place acute care ICU ) . Patients hypotensive systolic blood pressure read &lt; 110 mmHg time 3 day prior study entry Patients awake , alert , express pain discomfort relate catheter lock Patients exist local systemic infection define evidence fever ( body temperature &gt; 38.0o C two reading take least 10 minute apart one body temperature &gt; 38.3o ) follow within 24 hour enrollment : Pulse rate &gt; 100 beats/min . ; Respiratory rate &gt; 20/min . ; WBC count &gt; 12,000/mm3 , &lt; 4,000/mm3 differential count show &gt; 10 % band form . Patient still eligible study participant 's white blood cell count ( WBC ) outside normal limit due chemotherapy treatment underlying condition . Systolic blood pressure &lt; 90 mm Hg . Signs symptom localize catheterrelated infection ( tenderness and/or pain , erythema , swell , purulent exudate within 2 cm entry site ) Patients occlude ( partially totally ) catheter define inability either withdraw blood instill 3cc fluid without resistance catheter lumen Patients multiple coexist central venous catheter time enrollment enrol . Patients lock solution application interfere routine treatment underlying disease Patients known history allergic reaction ethanol , nitroglycerin , citrate . Female patient pregnant breast feed Patients disulfiram , metronidazole dependent alcohol Patients receive phosphodiesterase type 5 ( PDE5 ) inhibitor ( sildenafil , tadalafil , vardenafil ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>